Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 26;24(12):2133–2145. doi: 10.1093/neuonc/noac143

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Fig. 6. — Subpopulation-specific responses to treatment with BMP4. (A) Expression of the 10 most differentially expressed genes after treatment with BMP4 in GS832 (red) and GS612 (blue). NT = untreated. Heatmap of enriched KEGG pathways for upregulated (B) and downregulated (C) genes after treatment with BMP4 in GS832 (top panel) and GS612 (bottom panel). (D) Correlation with standard deviation of mean relative expression of ribosomal translation genes after 24 h treatment with BMP4 normalized to GAPDH and relative to untreated cells, compared to viability after 7 days of treatment with BMP4 (n = 3). (E) Top-20 differentially expressed genes in proliferating vs non-proliferating cells after BMP4. (F) Proportion of cells per cluster that do not upregulate ID1 and ID2 (non-responsive) vs those that do (responsive) after BMP4. (G) Heatmap illustrating the anti-correlation of GADD45A with ID1 and ID2. (H) Expression of BMPR2, NOG and HIG1A in untreated cultures GS832 and GS612.